A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Irccs Gaslini Institute, Genoa

The Children's Hospital of Philadelphia, Philadelphia

The Perelman School of Medicine - The University of Pennsylvania, Philadelphia

Hospital Universitario Ramon y Cajal, Pozuelo de Alarcón

Hospital Universitario Y Politecnico La Femerge, Valencia

Mayo Clinic, Rochester

Groupe Hospitalier Necker Enfants Malades, Paris

University of California San Francisco (UCSF), San Francisco

Hospital Italiano de Buenos Aires, Buenos Aires

Royal North Shore Hospital - New South Wales, Sydney

University Hospitals Leuven, Leuven

University of Alberta, Alberta Health Services (AHS), Edmonton

University Health Network (UHN), Toronto General Hospital (TGH), Toronto

Children's Hospital Capital Institute of Pediatrics (CIP), Beijing

Peking Union Medical College Hospital, Beijing

Shangai Children Medical Center, Shanghai

Tongi University - Tongi Hospital, Shanghai

Hopital Lariboisiere, Paris

Nagoya University Hospital, Nagoya

Aichi Children's Health and Medical Center, Ōbu

The University of Tokyo Hospital, Tokyo

Instituto Nacional De Rehabilitacion, Mexico City

Hospital Center Lisbon North, E.P.E- Hospital Santa Maria, Lisbon

Seoul National University Hospital, Seoul

Norrlands Universitetssjukhus, Umeå